Chemotherapy plus RA233 in the treatment of oat cell lung cancer.
One hundred and one patients with oat (small) cell lung cancer have been treated with CAVE [Cytoxan, Adriamycin, Vincristine, and etoposide (VP-16)] chemotherapy +/- RA233 (a platelet-inhibiting agent). There was no difference in disease-free interval, pattern of relapse, or survival between groups.
Lipton
A
A
Department of Medicine, Milton S. Hershey Medical Center, Hershey, PA 17033.
Harvey
H A
HA
Walker
B
B
Dixon
R
R
Valdivia
D
D
Barnes
S
S
Gordon
R
R
White-Hershey
D
D
Bartholomew
M J
MJ
Warzawski
N
N
D000206:Actuarial Analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000401:mortality; D003520:Cyclophosphamide / Q000008:administration & dosage; D004311:Double-Blind Method; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009012:Mopidamol / Q000627:therapeutic use*; D011034:Podophyllotoxin / Q000008:administration & dosage; D011446:Prospective Studies; D011743:Pyrimidines / Q000627:therapeutic use*; D011897:Random Allocation; D014750:Vincristine / Q000008:administration & dosage
D011743:Pyrimidines; D009012:Mopidamol; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011034:Podophyllotoxin